Prescription drug · BLA
Alymsys (Bevacizumab-maly) NDC 70121-1755
Bevacizumab 400 mg/16mL · Injection, Solution · Intravenous · Amneal Pharmaceuticals LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 70121-1755-1 | 70121175501 | 1 VIAL in 1 CARTON (70121-1755-1) / 16 mL in 1 VIALMarketed from Apr 15, 2022 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Alymsys
- Generic name (nonproprietary)
- bevacizumab-maly
- Active ingredients
- Bevacizumab — 400 mg/16mL
- Dosage form
- Injection, Solution
- Route
- Intravenous
- Labeler
- Amneal Pharmaceuticals LLCNDC labeler code 70121
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 761231
- Marketing start
- Marketing end
- Other FDA classes
- Vascular Endothelial Growth Factor Inhibitors (Mechanism)Vascular Endothelial Growth Factor-directed Antibody Interactions (Mechanism)
- Identifiers
- Product ID 70121-1755_ca8057b2-9aec-43bc-8525-cf8091433c71SPL ID ca8057b2-9aec-43bc-8525-cf8091433c71SPL set ID 6b4040a2-a5c5-4ff0-ab45-935d7e49cf78RxCUI 2599043, 2599049, 2599051, 2599052UNII 2S9ZZM9Q9VUPC 0370121175513, 0370121175414
- Pharmacologic class
- Vascular Endothelial Growth Factor Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeMed-Code curated
J9035 — Injection, bevacizumab, 10 mg
Billing unit: 10 mg. Units on the claim = dose given ÷ 10 mg.
Bevacizumab biosimilars have their own HCPCS codes.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N470121175501followed by a unit qualifier and the quantityPackage 70121-1755-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Alymsys is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. (1.1) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. (1.1) Limitations of Use: Alymsys is not indicated for adjuvant treatment of colon cancer. (1.1) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and…
Excerpt only. Read the full label for complete information.
About NDC 70121-1755
- What is NDC 70121-1755?
- 70121-1755 is the product NDC for Alymsys (bevacizumab-maly), Bevacizumab 400 mg/16mL injection, solution, listed with the FDA by Amneal Pharmaceuticals LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Alymsys (Bevacizumab-maly).
- What is the active ingredient?
- Bevacizumab.
- Who is the labeler?
- Amneal Pharmaceuticals LLC, NDC labeler code 70121. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Alymsys?
- 3 other product NDCs are listed under this name. See all Alymsys NDCs.
- Is there a related HCPCS / J-code?
- Yes: J9035, Injection, bevacizumab, 10 mg. See Billing references above.
Related NDCs: other Alymsys products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Alymsysbevacizumab-maly | Bevacizumab-maly 100 mg/4mL | Injection, SolutionIntravenous | Valorum Biologics, LLC | 85006-1754 | 85006-1754-01 |
| Alymsysbevacizumab-maly | Bevacizumab-maly 400 mg/16mL | Injection, SolutionIntravenous | Valorum Biologics, LLC | 85006-1755 | 85006-1755-01 |
| Alymsysbevacizumab-maly | Bevacizumab 100 mg/4mL | Injection, SolutionIntravenous | Amneal Pharmaceuticals LLC | 70121-1754 | 70121-1754-01 |
Other NDCs under BLA 761231
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Alymsysbevacizumab-maly | Bevacizumab 100 mg/4mL | Injection, SolutionIntravenous | Amneal Pharmaceuticals LLC | 70121-1754 |
| Alymsysbevacizumab-maly | Bevacizumab-maly 100 mg/4mL | Injection, SolutionIntravenous | Valorum Biologics, LLC | 85006-1754 |
| Alymsysbevacizumab-maly | Bevacizumab-maly 400 mg/16mL | Injection, SolutionIntravenous | Valorum Biologics, LLC | 85006-1755 |